Thank you for your continued interest in Biomoda, and apologies for the late reply. As you know, the primary focus for some time now has been finding funding to continue the optimization research and launch the pivotal trial. The management team is committed to seeing this effort through and has ongoing conversations with potential sources of funding. During this difficult time, no one is receiving a salary. The CEO, President and Board of Directors are diligently pursuing every opportunity to secure additional financing to fund operations and research.
In the meantime, we have strengthened our ties to the University of Texas Health Science Center at San Antonio and have begun planning next steps with their extraordinary research team. As soon as we secure financing, we will be able to begin optimization studies.
Until we have news to report to all shareholders, we have put the President's Columns and news releases on hold. For obvious reasons we cannot discuss any of our efforts to secure funding until we have a signed agreement with new investor(s). In the meantime, I would refer you to the SEC filings for additional information.
As always, thank you for your continued support and interest in the CyPath technology. And I promise you that we will communicate with all shareholders at the appropriate time.
Julie Anne Overton